Global Diagnostic Imaging Partnering Terms and Agreements 2015 to 2022


The Global Diagnostic Imaging Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
June 2022
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Diagnostic Imaging Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.


The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals.  This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:


  • Imaging
    • CT
    • Endoscope
    • Molecular and nuclear
      • PET
      • SPECT
    • MRI
    • Ultrasound
    • X ray
      • Angiography
      • Fluoroscopy
      • Mammography


This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2015.


This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2015. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements ( deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.


Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.


The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2015. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


Chapter 5 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2015. The chapter is organized by specific Diagnostic Imaging technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided organized by Diagnostic Imaging partnering company A-Z, deal type definitions and Diagnostic Imaging partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostic Imaging partnering and dealmaking since 2015.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostic Imaging technologies and products.


Key benefits


Global Diagnostic Imaging Partnering Terms and Agreements provides the reader with the following key benefits:


  • In-depth understanding of diagnostic deal trends since 2015
  • Comprehensive access to over 900 actual diagnostic imaging deals entered into by the world’s biopharma companies
  • Detailed access to actual diagnostic contracts enter into by the leading biopharma companies
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Diagnostic Imaging Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic imaging trends and structure of deals entered into by leading companies worldwide.


Global Diagnostic Imaging Partnering Terms and Agreements includes:


  • Trends in diagnostic imaging dealmaking in the biopharma industry since 2015
  • Access to over 900 diagnostic imaging contract documents
  • The leading diagnostic imaging deals by value since 2015
  • Most active diagnostic imaging  dealmakers since 2015
  • The leading diagnostic imaging partnering resources


In Global Diagnostic Imaging Partnering Terms and Agreements, the available contracts are listed by:


  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Specific technology target


Each deal title links to online deal records of actual diagnostic imaging partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. 


The Global Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive access to available contract documents for over 900 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise diagnostic rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Diagnostic Imaging Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:


  • In-depth understanding of diagnostic imaging deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 900 actual diagnostic imaging deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual diagnostic imaging contracts entered into by the most active companies
  • Identify leading diagnostic imaging deals by value since 2015
  • Identify the most active diagnostic imaging dealmakers since 2015
  • Insight into the terms included in a diagnostic imaging agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Diagnostic Imaging dealmaking


2.1. Introduction
2.2. Diagnostic Imaging partnering over the years
2.3. Most active Diagnostic Imaging dealmakers
2.4. Diagnostic Imaging partnering by deal type
2.5. Diagnostic Imaging partnering by therapy area
2.6. Deal terms for Diagnostic Imaging partnering
2.6.1 Diagnostic Imaging partnering headline values
2.6.2 Diagnostic Imaging deal upfront payments
2.6.3 Diagnostic Imaging deal milestone payments
2.6.4 Diagnostic Imaging royalty rates


Chapter 3 – Leading Diagnostic Imaging deals


3.1. Introduction
3.2. Top Diagnostic Imaging deals by value


Chapter 4 – Most active Diagnostic Imaging dealmakers


4.1. Introduction
4.2. Most active Diagnostic Imaging dealmakers
4.3. Most active Diagnostic Imaging partnering company profiles


Chapter 5 – Diagnostic Imaging contracts dealmaking directory


5.1. Introduction
5.2. Diagnostic Imaging contracts dealmaking directory


Chapter 6 – Diagnostic Imaging dealmaking by technology type



Appendix 1 – Diagnostic Imaging deals by company A-Z

Appendix 2 – Diagnostic Imaging deals by stage of development

Appendix 3 – Diagnostic Imaging deals by deal type

Appendix 4 – Diagnostic Imaging deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking


About Wildwood Ventures


Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures


Figure 1: Diagnostic Imaging partnering since 2015
Figure 2: Active Diagnostic Imaging dealmaking activity– 2015 to 2022
Figure 3: Diagnostic Imaging partnering by deal type since 2015
Figure 4: Diagnostic Imaging partnering by disease type since 2015
Figure 5: Diagnostic Imaging deals with a headline value
Figure 6: Diagnostic Imaging deals with an upfront value
Figure 7: Diagnostic Imaging deals with a milestone value
Figure 8: Diagnostic Imaging deals with a royalty rate value
Figure 9: Top Diagnostic Imaging deals by value since 2015
Figure 10: Most active Diagnostic Imaging dealmakers 2015 to 2022

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3B Pharmaceuticals, 3Derm Systems, 3DR Labs, 3M, 7D Surgical, 22nd Century, AAM Healthcare, Abbott Laboratories, Abbvie, Abcam, Abramson Cancer Center, Acacia Research, Accudata Systems, Accuray, Acibadem University, AC Immune, ACIST Medical Systems, Acoustic MedSystems, Actelion, Acutus Medical, AdAlta, Adaptiiv, Advanced Accelerator Applications, Advanced Animal Diagnostics, Advanced Cell Diagnostics, Advanced Chemistry Development, Advanced Guidance Technologies, Advanced Human Imaging, Advanced Nuclear Medicine Ingredients, Advanced Ultrasound Systems, Agfa HealthCare, Agilent Technologies, AG Mednet, Aidoc, Aiforia Technologies, AIG Hospitals, AI Metrics, AIM Specialty Health, Aircraft Medical, Akoya Biosciences, Akumin, Albany Molecular Research, Albert Einstein College of Medicine, Albert Einstein Healthcare Network, Alector, Alfasigma, Alibaba Health, Align Technology, AliHealth, Allegheny Technologies, Allergan, Alphaeon, Alpha Imaging, Alpinion Medical Systems, Altris, Alume Biosciences, Alzeca Biosciences, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimers Research UK, Amag Pharmaceuticals, Ambergen, Ambra Health, Ambry Genetics, Ambu, AmCad BioMed, A Menarini Diagnostics, American Brain Tumor Association, American College of Cardiology, American College of Chest Physicians, American Health Imaging, American Migraine Foundation, Amerinet, AMRA, AMRA Medical, Amydis, Analytics 4 Life, AnchorDx, Andor Technology, Antaros Medical, Applied Spectral Imaging, APRINOIA Therapeutics, Arc Medical Design, Aridea Solutions, Arivis, Arterys, Artialis, ARTMS Product, ARUP Laboratories, Ashvattha Therapeutics, Aspect Imaging, Aspen Imaging Healthcare, AstraZeneca, Athinoula A Martinos Center for Biomedical Imaging, Austin Health, Avantis Medical Systems, Avicenna Technology, AVRA Surgical, Aytu BioPharma, AZ Sint Lucas Hospital, BAMF Health, Banner Health, Baptist Health Care, Baxter International, Bayer, Bay Labs, Baylor College, Baylor College of Medicine, BayPAT, BC Technical, Beijing Podconley Pharmaceutical Technology and Development, BeMotion, Bethyl Laboratories, Biim Ultrasound, Bill and Melinda Gates Foundation, BioArctic Neuroscience, BioClinica, Biogen, Biokosmos, BIOLIFE4D, Biolife Science, BioMark Diagnostics, BiopharmX, Bioscience Pharma Partners, Biotechnology Innovation Organization, BioTek Instruments, BioTelemetry, Bioverativ, BJC HealthCare, Blackford, Blackfynn, BlackThorn Therapeutics, Blue Earth Diagnostics, Boehringer Ingelheim, BostonGene, Boston Medical Center, Boston Scientific, Bpifrance, Bracco Diagnostics, Bracco Imaging, Brain & Behavior Research Foundation, BRAIN Initiative, BrainLAB, Brainomix, Brain Scientific, BriaCell Therapeutics, Brigham and Women's Hospital, Broad Institute, Bruker, Bruker AXS, Bruker Energy & Supercon Technologies (BEST), Butantan Institute, Butterfly Network, BWX Technologies, C&C Irradiator Service, C4 Imaging, Calcivis, Cambridge Research Biochemicals, Canadian Teleradiology Services, Cancer Prevention and Research Institute of Texas, Cancer Targeted Technology, Canon, Canon BioMedical, Canon Lifecare Solutions, Cantel Medical, Capital X-ray, CapsoVision, Caption Health, Cardinal Health, Cardiologs, CardioNavix, Cardiowise, CareFusion, Carestream Health, Carl Zeiss, Carolinas Medical Center (CMC), Cartana, CarThera, Case Western Reserve University, Catabasis Pharmaceuticals, Catholic University Leuven, CBD Solutions, Celgene, CellSight Technologies, Celtic Biotech, Celularity, Censis Technologies, Center for Diagnostic Imaging (CDI), Centerline Biomedical, Centre for Addiction and Mental Health, Centre for Imaging Technology Commercialization, Centre for Probe Development and Commercialization, Centre for Structural Systems Biology, CerebraCell, CereHealth, Ceres, Cerevast Therapeutics, Cerveau Technologies, CgBio, Champalimaud Foundation, Change Healthcare, Check-Cap, CheckedUp, ChemImage, Children's Hospital Boston, Children's National Health System, China Development Industrial Bank, China Grand Pharma, China Grand Pharmaceutical, Chindex Medical Limited, Chinook Therapeutics, Chip-Man Technologies, Chonnam National University, Cincinnati Children’s Hospital Medical Center, Circle cardiovascular imaging, Cirle, City of Hope, Claritas HealthTech, Clarity Pharmaceuticals, Clear Guide Medical, ClearLight Diagnostics, ClearPoint Neuro, Cleveland Clinic, Client Outlook, Clinical Imaging Research Centre, Clovis Oncology, CNS Pharmaceuticals, Cohen Veterans Bioscience, Colorado State University, Columbia University, Columbia University Medical Center, Compact Imaging, Conavi Medical, ConcertAI, Confo Therapeutics, ContraVir Pharmaceuticals, Cook Medical, Cornell University, CorTechs Labs, CorVascular, Cosmo Pharmaceuticals, CrestOptics, CR Kennedy & Company, Cryolife, CS Medical, CureMetrix, Curium, CurveBeam, Cyclerion Therapeutics, Cyclopharm, Cyclotek, CymaBay Therapeutics, D&K Engineering, Dana-Farber Cancer Institute, Data Tecnica International, David H. Koch Institute for Integrative Cancer Research, Decathlon Capital Partners, Dectris, Deepcell, Deep Cube, Defense Advanced Research Projects Agency, Definiens, Dehaier Medical Systems, Denator, Densitas, Dent Neurologic Institute, Department of Defense, Department of Energy, Department of Veterans Affairs, DePuy, Device Technologies, DiA Imaging Analysis, Diannei Biotechnology, Diaprost, Diaspective Vision, Dicom Systems, Dilon Diagnostics, Disior, Diversigen, Draper Laboratories, DuChemBio, Duke University, Duke University Medical Center, Duquesne University, DySIS Medical, E.I. Medical Imaging, EchoNous, Echosens, Eckert & Ziegler, Eczacıbasi-Monrol, Edan Instruments, Edinburgh Innovations, Edinburgh Molecular Imaging, Edwards Lifesciences, Eigen, EIKOS Care Medical, Eisai, eKare, Eko, Electrical Geodesics, Elekta, Elesta, Eli Lilly, ElMindA, Embryo Ventures, EMC, Emergency Medicine Foundation, Emory Healthcare, Emory University, EMTensor, EndoChoice, EndoClot Plus, ENDRA Life Sciences, Enigma Biomedical, Enlitic, Entellus Medical, Envista, EOS Imaging, Epica Medical Innovations, Epredia, Epsilon, Erasmus University Medical Center, ERT, Esaote, Essen University Hospital, ETView Medical, Eureka Eurostars, European Prevention of Alzheimer’s dementia Initiative (EPAD), Event Cardio Group, EvoEndo, Evotec, Exact Imaging, Exact Sciences, Expesicor, Faes Farma, Faron Pharmaceuticals, FASTVet, FEI, Feinstein Institute for Medical Research, Ferrum Health, Finnish Funding Agency for Technology and Innovation (TEKES), FISBA, Flagship Biosciences, FlexDex, Fluidigm, Flywheel, Focal Healthcare, Food and Drug Administration (FDA), Frankenman Medical Equipment, Freenome, Fresenius, frog, Fujifilm, Fujifilm medical systems, FUJIFILM SonoSite, Fulcrum Therapeutics, Fusion Antibodies, Fuzionaire Diagnostics, Fuzionaire Radioisotope Technologies, Galderma, Gamma Medica, GCS Sesan, GE Healthcare, Genentech, GeneQuantum Healthcare, GenesisCare, Geneva University Hospitals, Genmab, Genomac Research Institute, Genome Institute of Singapore, Gentex, Geo-Med, German Cancer Research Center, Gestalt Diagnostics, GE Ventures, GI Reviewers, GlaxoSmithKline, Global Lung Cancer Coalition, Global Medical Solutions, gMed Canada, Golden Vine International, Goodwin Biotechnology, Google, Grand River Aseptic Manufacturing, Growshapes, Guardant Health, Guerbet, Guided Therapeutics, Guided Therapy Systems, Hadassah Medical Center, Hainan Sinotau Pharmaceutical, Halo Dx, Halt Medical, Hamamatsu Photonics, Hamilton Health Sciences, Harvard Medical School, Harvard University, Healius, HealthCare Konnect, HealthLytix, Healthmark Industries, HealthMyne, HealthTrust, Heartflow, HeartIT, HeartScore, Heidelberg Pharma, HekaBio, Hennepin County Medical Center, Henry Ford Health System, Henry M. Jackson Foundation, Henry Schein, Heritage Valley Health System, Hermes Medical Solutions, HistoIndex, Hitachi, Hitachi Aloka Medical, Hitachi Medical Systems Europe, Hologic, Horizon 2020, Hospital for Special Surgery, Hospital Services, HOYA Corporation, HP, HR Pharmaceuticals, Huami, Huma, Human Longevity, Human Metabolome Technologies, HuminTec, Hunan Xing Hang Rui Kang Bio-Technologies, Huvitz, Hybridyne Imaging Technologies, Hyperfine Research, IBA, IBA Molecular Imaging, Ibex Medical Analytics, IBM Watson Health, iCAD, Icagen, Icometrix, ICT Health, Ifa Systems, ii Ventures, Ikonopedia, Illumigyn, ImaBiotech, Image Analysis, ImageIQ, Image Stream Medical, ImaginAb, Imaging Advantage, Imaging Associates, Imagin Medical, Imago Systems, Imalogix, Imanova, Imbio, IMD Companies, Imeka, ImmersiveTouch, iMotions, Imperial College London, Imperial Innovations, Imricor Medical Systems, IMRIS, Indiana University, Indica Labs, Indivumed, Infervision, Inflazome, Infrared Cameras, Ingenza, inHEART, InnerOptic Technology, Innovate BC, Innovate UK, Innovative Manufacturing Cooperative Research Centre, Inscopix, InSightec, Institut Curie, Institut de Radiofarmacia Aplicada de Barcelona, Intalere, Intel, Intelerad Medical Systems, Intermountain Healthcare, International Association for the Study of Lung Cancer, International Progressive MS Alliance, Interscope, IntroMedic, Invenio Imaging, inVentiv Health, inviCRO, IQ-AI, IRE Elit, IRIS, IRIS International, iSchemaView, Isologic Innovative Radiopharmaceuticals, Isotope Technologies Garching, Isotopia Molecular Imaging, ITEL, Item, ITEM Medical Technologies, Iterative Scopes, iThera Medical, ITM Isotopen Technologien, Ives EEG Solutions, IXICO, Jain Foundation, James S. McDonnell Foundation, Jana Care, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jazz Pharmaceuticals, JFE Engineering, Jiangsu Vedkang Medical Science and Technology, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Juama, Jubilant DraxImage, Jubilant Radiopharma, Juntendo University, K2M, KA Imaging, Kanazawa University, Kanteron Systems, Karolinska University Hospital, Keck School of Medicine of USC, Keio Gijuku University, Kent Imaging, Kettering Health, Kheiron Medical Technologies, Kings College London, Konica Minolta, Korea Pharma, KromaTiD, KUB Technologies, Laboratory Corporation of America, Labrador Technologies, Lambell Ghana, Lantheus Holding, Lantheus Medical Imaging, Lee Health, Lee Moffitt Cancer Center, Lehigh University, Leica Biosystems, Leica Microsystems, Leiden University, LEO Pharma, LI-COR Biosciences, Life Image, LifeOmic, LifeTech Scientific, Lighthouse Imaging, Lightlake Therapeutics, Lightpoint Medical, Limaca Medical, Lipidomics Consulting, LOK, Lucence, Lumicell, Lunaphore, Lundbeck, Lunit, Luxel, M*Modal, Maastricht University, Macquarie University, Magellan Health Services, Magic Leap, Magle Chemoswed, Magnetic Insight, Major Health Partners, Mallinckrodt Pharmaceuticals, Marien Hospital, Marubeni, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Materialise, Matrox, Mauna Kea Technologies, MaxQ AI, Mayo Clinic, McGill University, MD Anderson Cancer Center, Medassets, MedAxiom, MedCom, Medexus Pharmaceuticals, MEDIAN Technologies, Medical College of Wisconsin, Medical Imaging, Medical One, Medical Research Council, Medidata Solutions, Medigus, MedImmune, MED Institute, Medis, Mediso, Mednax, Medovate, Medpace, medPhoton, MedQuest, Medtronic, Medx, MedyMatch, Meito Sangyo, Melanoma Research Alliance, MemorialCare Health System, Memorial Hermann Health System, Memorial Sloan Kettering Cancer Center, Merck and Co, Merge Healthcare, Merit Medical Systems, Metaoptima Technology, Methapharm, Methodist Hospital Houston, Mevion Medical Systems, Michael J Fox Foundation, Michigan State University, Micro-Tech Endoscopy, Micron Technologies, MicroPort Sorin CRM (Shanghai), Microsoft, Mighty Oak Medical, MILabs, Mimetas, MindPeak, Mindray Medical International, Ministry of Health (Turkey), Minogue Medical, Minomic, MinXray, Misonix, Mission Health, MITRO Biotech, MOBILion Systems, Mobius Imaging, Molecular Devices, MolecularMD, MolecuLight, Molnlycke Health Care, Monopar Therapeutics, Montreal Neurological Institute-Hospital, Motus GI Medical Technologies, MRI Interventions, MR Solutions, Munich Technical University, Myocardial Solutions, n3D Biosciences, Nanjing Micro-Tech, Nano-X Imaging, NanoMab Technology, Nanosonics, NASA, National Cancer Center, National Cancer Institute, National Cancer Institute of Mexico, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Healthcare Services (NHS), National Heart, Lung and Blood Institute, National Institute of Biomedical Imaging and Bioengineering, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Physical Laboratory, National Research Nuclear Center, National Science Foundation, National Ultrasound, National University of Ireland, Galway (NUI Galway), Natus Medical, Nautilus, Naval Medical Research Center, Navidea Biopharmaceuticals, Navigate Surgical Technologies, NDR Medical Technology, Nektar Therapeutics, Nelson Laboratories, Nephros, NervGen Pharma, NetScientific, Neuro42, Neuroelectrics, NeuroLogica, NeuroNexus, NeuroScience Associates, NeuroVision Imaging, NeuSoft Medical Technologies, Neuvogen, New England Complex Systems Institute, Newmars Group, New York University, NextGate, Nico, Nihon Medi-Physics, Nikon Corporation, Nikon Instruments, Ninepoint Medical, Nordicneurolab, Nordion, Norgine, Noria Therapeutics, Norsk medisinsk syklotronsenter, Northeastern University, North Mississippi Health Services, NorthStar Medical Radioisotopes, Northwell Health, Northwestern Medicine Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University, NovAliX, Novant Health, Novarad, Novara Therapeutics, Novarix, Novartis, Novo Nordisk, NTT Data, Nuance Healthcare, Nuclear Diagnostic Products, Nucleo de Bioensaios Biossintese e Ecofisiologia de Produtos Naturais, Nucliber, numares, NuVasive, Nvidia, nView Medical, NX Development, NYU Grossman School of Medicine for Preclinical and Clinical Research, NYU Langone Medical Center, NZ Technologies, Oak Ridge National Laboratory, Occlugel, Olea Medical, Olympus, Olympus Respiratory America, OmniVision Technologies, Oncidium Foundation, OncoBeta, OncoNano Medicine, OncoVision, OnDemand 3D, One Lambda, OneMedNet, OnLume Surgical, ON Semiconductor, OphtAI, Optasia Medical, Optellum, Optibrand, Optim, Optoacoustics, Optomed, Optos, Optovue, OracleBio, Oregon Health Sciences University, OrthoGrid Systems, Orthopaedic Research UK, Osaka University, Oslo University Hospital, Otsuka, Otsuka America Pharmaceutical, oVio Technologies, Ovizio, Owkin, Owlstone Medical, Pacific Dental Services, Paige, Pall Corporation, Panacea Pharmaceuticals, Pancreatic Cancer Action Network, Paracelsus Clinics, Patient-Centered Outcomes Research Institute (PCORI),, Paul G Allen Family Foundation, Pennsylvania State University, Pentax, PENTAX Medical, Pepscan, Peramare Pharmaceuticals, Perelman School of Medicine, PerkinElmer, Perry Baromedical, Perspectum Diagnostics, PETNET Solutions, Pfizer, PharmaCare Management, PharmaLogic, PharmaVentures, Phase Holographic Imaging, PhenoVista Biosciences, Philips, Philochem, Phoenix Children’s Hospital, Photometrics, Physio-Control, Phytronix Technologies, Ping An Ventures, Planmeca, Planmed, Plus Therapeutics, POINT Biopharma, Polarean Imaging, Positron, Precision Image Analysis, Precision Lens, Precision Optics, Premier Inc, Presagen, PrinterPrezz, Probo Medical, Profil Institute for Clinical Research, Profound Medical, Progenics Pharmaceuticals, Promaxo, Promedica Bioelectronics, ProPath, Proprio, Proscia, Qlarity Imaging, Qualigen, Quality Electrodynamics, QuantalRF, Quest Diagnostics, Quibim,, qynapse, Radboud University Nijmegen Medical Centre, Radiology Oncology Systems, Radiopharm Theranostics, Radlink, RadNet, Rakuten Medical, RAM-Tech, RapidAI, RAW, RaySearch Laboratories, ReadCoor, ReCor Medical, Redlen Technologies, RefleXion Medical, RegenLab, Remidio Innovative Solutions, Renovo, Resolve Biosciences, Resonance Health, RetinAI Medical, RetiSpec, Reveal Pharmaceuticals, RFPi, Richardson Healthcare, Richardson RFPD, Riverain Medical, Riverside Research, RMD Instruments, Roche, ROCOL, Rose F Kennedy Intellectual and Developmental Disabilities Research Center, ROTOP Pharmaka, Rouumtech, Royal Philips Electronics, RSA Biomedical, Rutgers University, Salk Institute, Salud Digna, Samsung Electronics, Sanford Health, San Raffaele Hospital, Sanuwave Health, Saphena Medical, Satisfai Health, Sayre Therapeutics, SciBase, Science 37, Science Exchange, Scil Proteins, Scintica Instrumentation, Scintomics, Screenpoint Medical, SeaSpine, SecondWave Systems, Sectra, Seibersdorf Laboratories, Sensus Healthcare, SerenaGroup, Shanghai Pharmaceutical, Shared Medical Services, Sheikh Zayed Institute for Pediatric Surgical Innovation, Shimadzu, Shineco, Shriners Hospital for Children, Siemens, Siemens Healthcare, Siemens Healthineers, SimonMed Imaging, Singapore Bioimaging Consortium, Sinomed, Sirona Direct, Sirtex Medical, SkinCure Oncology, Skyline Urology, Small Business Innovation Research, SmartBreast, Smart Medical Systems, Smilow Cancer Hospital at Yale-New Haven (SCH), Smith & Nephew, Sofie Biosciences, SolaranRx, Solis Mammography, SomaServe, Sonic Healthcare, Sono-Tek, SonoScape Medical, Sophia Genetics, Soricimed Biopharma, SourceMark Medical, SpePharm, Spesana, SPI Medical, Spinal Elements, Spotlight Innovation, SST Group, Stand Up To Cancer, Stanford Health Care, Stanford University, Stanford University School of Medicine, StemoniX, Stereotaxis, Stockholm University, Storm ID, Stratasys, Stratis Medical, Stryker, Subtle Medical, Sumitomo Cryogenics, Sunnybrook Health Sciences Centre, Super Resolution Technologies, SuperSonic Imagine, Surfacide, Surgical Theater, Susan G. Komen for the Cure, Swiss Institute of Allergy and Asthma Research, Swixx Biopharma, Synaptive Medical, SyntheticMR, Sysmex, T3 Labs, Takeda Pharmaceutical, Tau Consortium, Techcyte, Teijin, Tel Aviv University, Teledyne Technology, TeleMammography Specialists, Telemedicine Solutions, Telix Pharmaceuticals, Temple University, Terason, Teva Pharmaceutical Industries, The Hospital for Sick Children, The Joint Pathology Center, The Nemours/Alfred I duPont Hospital for Children, Theragnostics, TheraPanacea, Therapixel, Thomas Jefferson University, Tissue Analytics, Tokyo Metropolitan Institute of Gerontology, Toronto Innovation Acceleration Partners, toSense, Toshiba America Medical Systems, Toshiba Medical Systems Corporation, Touchstone Medical Imaging, Tracey Technologies, Transcriptome Sciences, Translational Research Institute for Space Health, Triad Isotopes, Triage Technologies, Trivitron Healthcare, Tromp Medical, Trophogen, TrovaGene, TTG Imaging Solutions, TumorGen, Turku PET Center, Turner Imaging Systems, UK Biobank, Ultivue, UltraSight, Unetixs Vascular, Unified Women's Clinical Research, United Imaging Healthcare, United States Military Cancer Institute, University City Science Center, University College London, University of Alabama at Birmingham, University of Arizona, University of Augsburg, University of California, University of California, San Diego, University of California, San Diego (UCSD) School of Medicine, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Florida, University of Glasgow, University of Heidelberg, University of Hong Kong, University of Iowa, University of Konstanz, University of Lausanne, University of Leeds, University of Leuven, University of Louisville, University of Manchester, University of Maryland, University of Massachusetts Medical School, University of Melbourne, University of Miami, University of Michigan, University of Michigan Medical School, University of Minnesota, University of New Mexico, University of North Carolina, University of North Texas Health Science Center, University of Oklahoma, University of Oulu, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rennes, University of Rochester, University of South Carolina, University of Southern California, University of Texas, University of Texas Southwestern Medical Center, University of Toronto, University of Tubingen, University of Utah, University of Virginia, University of Washington, University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center (UWCCC), University of Wollongong, University of Zurich, Uppsala University, UroPartners,, US Air Force, USARAD, US Government, US Radiology Specialists, Vanderbilt University, Vantage Endoscopy, Varex Imaging, Varian Medical Systems, Veracyte, Verge Genomics, Verily, VIB, Vida Diagnostics, Vidence, Viewpoint Molecular Targeting, ViewRay, Vigilant Biosciences, VIPUN Medical, Viral Sign, Virginia Polytechnic Institute and State University, Virginia Tech Intellectual Properties, Virtual Imaging, VirtualScopics, Visage Imaging, Visaris Americas, Visikol, VisionQuest Biomedical, Visiopharm, VisualDx, Vital Images, Vithas Group, Vizient, Volk Optical, Volpara Solutions, VOTIS Subdermal Imaging Technologies, VuCOMP, VU Medical Center, VUNO, WaferGen Biosystems, WakeMed Health & Hospitals, Wallace H. Coulter Foundation, Walloon Region Investment Fund, Wandong Medical Equipment, Waseda University, Washington University in St Louis, WaVe Lifesciences, Wayne State University, Weifang Jianyi Medical Devices, Weill Cornell Medical College, Weizmann Institute, Wellman Center For Photomedicine, WellSpan York Hospital, Westchester Medical Center Health Network, Weston Brain Institute, Whiterabbit, Wilex, William Osler Health System, Women & Infants Hospital of Rhode Island, WorldCare Clinical, Wound Care Advantage, Xavier University of Louisiana, Xiel, XLIM, Xoran Technologies, XPRIZE Pandemic Alliance, XRpro Sciences, Xstrahl, Y-mAbs Therapeutics, Yale School of Medicine, Yale University, Yitu Medical, Yokogawa Electric, York Instruments, York University, ZAP Surgical Systems, Zebra Medical Vision, Zebra technologies, Zecotek Photonics, Zepp Health, Ziehm Imaging, Zimmer Biomet, Zionexa, Zonare Medical Systems

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.